NEW YORK, NY — (Marketwire) — 10/28/11 — TriMarkPublications.com cites in its newly published ” Diagnostic Testing Markets” report that the U.S. diagnostic testing market will surpass $2.4 billion by 2016. For more information, visit: .
Both the U.S. and the world market for diagnostic testing are expected to grow at roughly 8% compound annual growth rates through 2016. Key growth areas include the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Significant diagnostic testing growth is also anticipated internationally, particularly in the European Union, where Germany, Italy and France each showed significant revenue in 2010.
The ” Diagnostic Testing Markets” report covers:
Acute myocardial infarction (AMI).
Heart failure.
BNP.
Myoglobin.
Homocysteine (Hcy).
C-reactive protein (CRP).
Pulmonary embolism (PE) (D-dimer test).
Low-density and high-density lipoproteins (LDL and HDL).
Stroke.
CK-MB and cardiac enzymes.
Albumin.
used in clinical decisions.
in renal failure.
Troponins in non-ischemic heart disease.
Cardiac panels.
Point of care (POC) .
The ” Diagnostic Testing Markets” report examines companies manufacturing equipment and supplies in the world. Companies covered include: Abbott, Alere, Ani, Axis-Shield, Bayer, Beckman Coulter, Biosite, Johnson & Johnson, LifeSign, PreMD, Randox, Response, Roche, Siemens, Sierra Resources and Spectral Diagnostics.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK